AvalehtSUNPHARMA • NSE
add
Sun Pharmaceutical Industries Ltd
Viimane sulgemishind
1609,70 ₹
Tänane vahemik
1603,10 ₹ - 1622,50 ₹
Aasta vahemik
1553,05 ₹ - 1960,35 ₹
Turuväärtus
3,88 trln INR
Keskmine maht
2,58 mln
P/E suhe
37,23
Dividendimäär
0,99%
Põhibörs
NSE
Börsiuudised
CNBC
18 tunni eest
S&P 500 fights for another record — plus, Eaton signals big data center opportunity
0,048%
1,62%
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (INR) | juuni 2025info | Y/Y muutus |
|---|---|---|
Käive | 138,51 mld | 9,47% |
Põhitegevusega seonduv kulu | 76,65 mld | 9,90% |
Puhastulu | 22,79 mld | −19,64% |
Puhaskasumimarginaal | 16,45 | −26,60% |
Puhaskasum aktsia kohta | 11,98 | 1,48% |
EBITDA | 39,63 mld | 10,32% |
Tõhus maksumäär | 27,51% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (INR) | juuni 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 261,23 mld | 36,84% |
Kogu vara | — | — |
Kõik kohustused | — | — |
Kogu omakapital | 724,86 mld | — |
Emiteeritud aktsiate arv | 2,40 mld | — |
Hinna ja väärtuse suhe P/B | 5,35 | — |
Varade tasuvus | — | — |
Kapitali tasuvus | 11,26% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (INR) | juuni 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 22,79 mld | −19,64% |
Põhitegevuse rahakäive | — | — |
Investeeringute raha | — | — |
Finantseerimise raha | — | — |
Raha ja raha ekvivalentide muutus | — | — |
Tasuta rahavoog | — | — |
Teave
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Asutatud
1983
Peakontor
Veebisait
Töötajate arv
43 000
